Clear Harbor Asset Management LLC lowered its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 75.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 11,702 shares of the biopharmaceutical company’s stock after selling 36,180 shares during the period. Clear Harbor Asset Management LLC’s holdings in Gilead Sciences were worth $948,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in GILD. Penserra Capital Management LLC lifted its stake in Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 144 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Gilead Sciences in the second quarter worth about $147,000. Harel Insurance Investments & Financial Services Ltd. lifted its stake in Gilead Sciences by 29.3% in the second quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,120 shares of the biopharmaceutical company’s stock worth $150,000 after purchasing an additional 480 shares during the last quarter. Rowland & Co. Investment Counsel ADV bought a new stake in Gilead Sciences in the second quarter worth about $153,000. Finally, Capstone Investment Advisors Netherlands B.V. bought a new stake in Gilead Sciences in the second quarter worth about $172,000. Institutional investors own 75.94% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ GILD) opened at $72.71 on Friday. The company has a market cap of $95,383.76, a P/E ratio of 8.28, a P/E/G ratio of -1.22 and a beta of 1.13. Gilead Sciences, Inc. has a 12 month low of $63.76 and a 12 month high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.86%. The ex-dividend date is Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is 23.69%.
In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction on Friday, December 1st. The shares were sold at an average price of $74.98, for a total value of $5,498,508.34. Following the transaction, the insider now directly owns 3,070,099 shares of the company’s stock, valued at $230,196,023.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gregg H. Alton sold 25,000 shares of Gilead Sciences stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $82.65, for a total transaction of $2,066,250.00. The disclosure for this sale can be found here. Insiders sold 494,999 shares of company stock worth $37,404,139 over the last ninety days. Corporate insiders own 1.30% of the company’s stock.
GILD has been the subject of several analyst reports. TheStreet raised shares of Gilead Sciences from a “c+” rating to a “b-” rating in a research note on Thursday, September 7th. Deutsche Bank reissued a “buy” rating and issued a $81.00 price objective on shares of Gilead Sciences in a research note on Thursday, August 31st. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 price objective for the company in a research note on Thursday, August 31st. Berenberg Bank set a $86.00 price objective on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, August 29th. Finally, Credit Suisse Group set a $79.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research note on Monday, August 28th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $85.03.
TRADEMARK VIOLATION NOTICE: “Gilead Sciences, Inc. (GILD) Shares Sold by Clear Harbor Asset Management LLC” was posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.com-unik.info/2017/12/24/gilead-sciences-inc-gild-shares-sold-by-clear-harbor-asset-management-llc.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.